Clinical Trials Logo

Malignant Solid Tumor clinical trials

View clinical trials related to Malignant Solid Tumor.

Filter by:

NCT ID: NCT02518958 Completed - Lymphoma Clinical Trials

A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab

PRIMETIME
Start date: July 21, 2015
Phase: Phase 1
Study type: Interventional

This is a dose escalation protocol to determine the feasibility of co-administration of RRx-001 and nivolumab. Immune surveillance is an endogenous mechanism to cause remission of neoplastic growth. Epigenetic agents like RRx-001 are associated not only with enhanced gene transcription and restored expression of silenced genes but also with increased expression of pro-inflammatory mediators, upregulation of PD-L1 on tumor cells and de-repression of antigens that promote immune recognition of tumors. It is hypothesized that RRx-001, will prime or sensitize to immune checkpoint therapy targeting PD-1 interaction with nivolumab.

NCT ID: NCT02252211 Completed - Clinical trials for Malignant Solid Tumor

Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers

LUD2014-002
Start date: December 9, 2014
Phase: Phase 1
Study type: Interventional

This was a Phase 1, dose-escalation, non-randomized, open-label, single-center study of DS-8895a in patients with advanced or metastatic Ephrin type-A receptor 2 (EphA2)-positive cancers. The primary study objective was to determine the safety of DS-8895a, with secondary objectives of determining the biodistribution, tumor uptake (bioimaging), pharmacokinetics (PK), antitumor and pharmacodynamic response, and correlations between pharmacodynamics and clinical outcomes, as appropriate.

NCT ID: NCT02096341 Terminated - Lymphomas Clinical Trials

A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

Start date: April 2014
Phase: Phase 1
Study type: Interventional

To investigate the dosage of RRx-001 by the subcutaneous route.

NCT ID: NCT01846429 Terminated - Pain Clinical Trials

Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain

Start date: September 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to: - Determine how well people tolerate sodium bicarbonate taken by mouth in higher doses than those usually given for heartburn. - Determine if sodium bicarbonate can reduce cancer-related pain.

NCT ID: NCT01670175 Completed - Clinical trials for Malignant Solid Tumor

Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors

Start date: August 2012
Phase: Phase 1
Study type: Interventional

This is a Phase I study of the combination of three drugs: sirolimus, cyclophosphamide, and topotecan. This is the first study to evaluate the safety and clinical activity of the combination of oral sirolimus, oral cyclophosphamide and oral topotecan in pediatric and young adult patients with relapsed and refractory solid tumors. In this phase I study, the mTOR inhibitor sirolimus will be administered in combination with oral cyclophosphamide and oral topotecan to children with relapsed or refractory solid tumors. The primary aim of this study is to recommend a phase II dose schedule and describe the toxicity of this combination. Myelosuppression will be a targeted toxicity.

NCT ID: NCT01648764 Completed - Solid Tumor Clinical Trials

A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread

Start date: September 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate two different dosing regimens of LY2334737 in participants with cancer that is advanced and/or has spread to other parts of the body. Information about side effects will be collected.

NCT ID: NCT01632696 Terminated - Clinical trials for Malignant Solid Tumor

Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors

Start date: June 2012
Phase: Early Phase 1
Study type: Interventional

Tumor Imaging of I-124 PGN65 in Solid Tumors

NCT ID: NCT01606748 Completed - Clinical trials for Malignant Solid Tumor

A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin

Start date: August 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug interactions between necitumumab and gemcitabine-cisplatin.

NCT ID: NCT01567163 Completed - Clinical trials for Malignant Solid Tumor

A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

Start date: July 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effect of concomitant ramucirumab on the pharmacokinetics of docetaxel in participants with advanced malignant solid tumors. Participants who do not complete both Cycle 1, Day 1, and Cycle 2, Day 1 according to schedule will be replaced for the purpose of analysis; these participants may continue to receive study therapy. No dose reductions, delayed or missed doses are allowed during Cycles 1 and 2.

NCT ID: NCT01515306 Completed - Clinical trials for Malignant Solid Tumor

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Start date: July 19, 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate whether there are no clinically significant pharmacokinetic effects of concomitant ramucirumab (IMC-1121B) on paclitaxel by investigating the pharmacokinetics (PK) of each in participants with advanced malignant solid tumors. Part A of this study will investigate the potential of concomitant ramucirumab (IMC-1121B) to affect the pharmacokinetics of paclitaxel. Part B of this study will investigate the pharmacokinetics of ramucirumab (IMC-1121B) as monotherapy.